J Pathol Transl Med.  2021 Mar;55(2):112-117. 10.4132/jptm.2020.11.30.

A study of pathological characteristics and BRAF V600E status in Langerhans cell histiocytosis of Vietnamese children

• Phan TDA
• Phung BG
• Duong TT
• Hoang VA
• Ngo DQ
• Trinh NDT
• Tran TT

• KMID: 2513896
• DOI: http://doi.org/10.4132/jptm.2020.11.30

Abstract

Background
Langerhans cell histiocytosis (LCH) is more common in children than adults and involves many organs. In children, the BRAF V600E mutation is associated with recurrent and high-risk LCH.
Methods
We collected paraffin blocks of 94 pediatric LCH patients to detect BRAF V600E mutation by sequencing. The relationship between BRAF V600E status and clinicopathological parameters were also critically analyzed.
Results
BRAF V600E mutation exon 15 was detected in 45 cases (47.9%). Multiple systems LCH showed a significantly higher BRAF V600E mutation rate than a single system (p=.001). No statistical significance was evident for other clinical characteristics such as age, sex, location, risk organs involvement, and CD1a expression.
Conclusions
In Vietnamese LCH children, the proportion of BRAF V600E mutational status was relatively high and related to multiple systems.

Keyword

Langerhans cell histiocytosis; BRAF V600E mutation; Sequencing

Figure

• 

  Fig. 1 Langerhans cell histiocytosis on hematoxylin and eosin staining: (A) skin lesion, (B) soft tissue of the head and neck, (C) bone lesion, and (D) lymph node lesion.

• 

  Fig. 2 The BRAF V600E status in pediatric Langerhans cell histiocytosis.

Reference

References

1. Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000–2004. Pediatr Blood Cancer. 2008; 51:71–5.

2. Salotti JA, Nanduri V, Pearce MS, Parker L, Lynn R, Windebank KP. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child. 2009; 94:376–80.

3. Arceci RJ. The histiocytoses: the fall of the Tower of Babel. Eur J Cancer. 1999; 35:747–67.

4. Gadner H, Minkov M, Grois N, et al. Therapy prolongation improved outcome in multisystem Langerhans cell histiocytosis. Blood. 2013; 121:5006–14.

5. Abla O, Weitzman S. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition. Hematology Am Soc Hematol Educ Program. 2015; 2015:565–70.

6. Birbeck MS, Breathnach AS, Everall JD. An electron microscope study of basal melanocytes and high-level clear cells (Langerhans cell) in vitiligo. J Investig Dermatol. 1961; 37:51–64.

7. Minkov M. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs. 2011; 13:75–86.

8. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417:949–54.

9. Fiskus W, Mitsiades N. B-Raf inhibition in the clinic: present and future. Annu Rev Med. 2016; 67:29–43.

10. Wooster R, Futreal AP, Stratton MR. Sequencing analysis of BRAF mutations in human cancers. Methods Enzymol. 2006; 407:218–24.

11. Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012; 10:85.

12. Heritier S, Emile JF, Barkaoui MA, et al. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol. 2016; 34:3023–30.

13. Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2015; 212:281.

14. Mehes G, Irsai G, Bedekovics J, et al. Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry. Am J Surg Pathol. 2014; 38:1644–8.

15. Brown NA, Furtado LV, Betz BL, et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014; 124:1655–8.

16. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012; 120:2700–3.

17. Nelson DS, Quispel W, Badalian-Very G, et al. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood. 2014; 123:3152–5.

18. Sahm F, Capper D, Preusser M, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 2012; 120:e28–34.

19. Satoh T, Smith A, Sarde A, et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS One. 2012; 7:e33891.

20. Ballester LY, Cantu MD, Lim KP, et al. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis. Hematol Oncol. 2018; 36:307–15.

21. Alayed K, Medeiros LJ, Patel KP, et al. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases. Hum Pathol. 2016; 52:61–7.

22. Roden AC, Hu X, Kip S, et al. BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am J Surg Pathol. 2014; 38:548–51.

23. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010; 116:1919–23.

24. Ozer E, Sevinc A, Ince D, Yuzuguldu R, Olgun N. BRAF V600E mutation: a significant biomarker for prediction of disease relapse in pediatric Langerhans cell histiocytosis. Pediatr Dev Pathol. 2019; 22:449–55.

25. Sasaki Y, Guo Y, Arakawa F, et al. Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan. Hematol Oncol. 2017; 35:329–34.

26. Go H, Jeon YK, Huh J, et al. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology. 2014; 65:261–72.

27. Liu X, Zhang Y, Zhou CX. High prevalence of BRAF V600E mutations in Langerhans cell histiocytosis of head and neck in Chinese patients. Int J Surg Pathol. 2019; 27:836–43.